rg547
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2005 (NCT00400296)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cyclin-dependent kinase 2INHIBITOR
CDK2 inhibitor
- Cyclin-dependent kinase 4INHIBITOR
CDK4 inhibitor
- Cyclin-dependent kinase 1INHIBITOR
CDK1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N- Mol. weight
- 441.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL384304 ↗
Also known as
- r-547
- r-547
- rg547
- rg-547
- rg-547
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00400296 | Phase 1 | May 1, 2005 | Roche |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 1 | 1 | 1 | 2005 |
1 organizations
Page 1 / 1